SCHEMBL29818282

SCHEMBL29818282

CC1(C)CCc2ccc(Cl)nc21

nearest known ligand 0.33

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.33
HTR2A P28223 4/20 0.33
HTR2C P28335 4/20 0.33
HTR2B P41595 3/20 0.32
KCNH2 Q12809 1/20 0.31
HTR3E A5X5Y0 1/20 0.31
HTR3B O95264 1/20 0.31
HTR3A P46098 1/20 0.31
HTR3D Q70Z44 1/20 0.31
HTR3C Q8WXA8 1/20 0.31
SRD5A1 P18405 1/20 0.30
EEF2K O00418 1/20 0.30
ESR1 P03372 1/20 0.30
ESR2 Q92731 1/20 0.30
KDM1A O60341 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25196294 1.00 AR (0.33) ARHTR2AHTR2CHTR2BKCNH2
SCHEMBL22532038 0.82 ESR1 (0.31) ARESR1ESR2
SCHEMBL30496843 0.82 ESR1 (0.31) ARESR1ESR2
SCHEMBL23376857 0.80 ESR1 (0.36) HTR2AHTR2CHTR2BKCNH2ESR1
SCHEMBL29726035 0.78 AR (0.32) ARHTR2AHTR2CHTR2B
SCHEMBL846418 0.78 AR (0.32) ARHTR2AHTR2CHTR2B
SCHEMBL17441673 0.77 KDM1A (0.40) KDM1A
SCHEMBL17441194 0.76 KDM1A (0.34) KDM1A
SCHEMBL23364873 0.76 MAP3K14 (0.38) ESR1ESR2
SCHEMBL22532060 0.76 MAP3K14 (0.38) ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4284804-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS Schrödinger, Inc. (US) 2023-12-06 EP disclosed
CN-117120442-A Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders 薛定谔公司 2023-11-24 CN disclosed
WO-2022164789-A9 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS SCHRÖDINGER, INC. (US) 2023-05-25 WO disclosed
WO-2022164789-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS SCHRÖDINGER, INC. (US) 2022-08-04 WO disclosed